When a Black patient with hypertension does not respond to losartan, the instinct is often to blame adherence or diet. But a growing body of evidence points to a genetic wall: the CYP3A5 enzyme. Roughly 70% of people of African descent carry a functional CYP3A5*1 allele that rapidly metabolizes several ARBs, shortening their half-life and blunting blood-pressure lowering. This is not a matter of race as a social construct — it is a pharmacogenomic difference with real dosing consequences.

The Genetic Wall in Drug Metabolism

The CYP3A5 enzyme belongs to the cytochrome P450 family, responsible for metabolizing roughly half of all prescription drugs. Most people of European or Asian ancestry carry a nonfunctional variant (CYP3A5*3) that produces little to no active enzyme. But in individuals of African ancestry, the functional CYP3A5*1 allele is common — some estimates put carrier frequency near 50–70%.

For ARBs such as losartan and irbesartan, CYP3A5 catalyzes a key oxidative step. In expressers — those with at least one *1 allele — the drug is cleared from the bloodstream more quickly. A study from UNC Chapel Hill found that losartan's half-life in CYP3A5 expressers was roughly 40% shorter than in non-expressers, and the area under the curve (a measure of total drug exposure) was reduced by about 30%.

This accelerated clearance translates directly into lower receptor blockade at standard doses. The effect is most pronounced for losartan, which is a prodrug that relies on conversion to its active metabolite, E-3174. CYP3A5 also metabolizes E-3174, compounding the loss of efficacy.

Irbesartan, which is not a prodrug, is also affected, though perhaps less dramatically. Candesartan and valsartan appear less dependent on CYP3A5, but the evidence is still limited. The net effect is that a one-dose-fits-all approach to ARB prescribing systematically underdoses a large subset of Black patients.

How CYP3A5 Polymorphism Shifts Dosing

The clinical consequence is straightforward: CYP3A5 expressers often need higher ARB doses to achieve the same blood-pressure reduction. Some pharmacokinetic studies suggest that doubling the standard losartan dose — from 50 mg to 100 mg daily — can partially overcome the accelerated clearance, but even then, trough levels may remain lower than in non-expressers on 50 mg.

Data from the Alliance for Clinical Trials in Oncology, which included a substantial proportion of Black participants, showed that losartan at 50 mg daily produced a mean systolic blood-pressure reduction of only 4–6 mmHg in CYP3A5 expressers, compared with 10–12 mmHg in non-expressers. This gap is clinically meaningful — a difference of 5 mmHg in systolic pressure is associated with roughly a 20% difference in cardiovascular event risk over five years.

Some researchers have proposed using urinary sodium excretion as a biomarker to guide ARB dosing in Black patients. The idea is that ARB efficacy is partly determined by sodium status, and that CYP3A5 expressers may have a blunted natriuretic response. However, this approach has not been validated in large trials and is not yet ready for routine practice.

The practical takeaway is that if an ARB is chosen for a Black patient, the starting dose should be at the higher end of the approved range, and blood pressure should be rechecked within two weeks. If the response is inadequate, the dose should be titrated upward — up to the maximum labeled dose — before switching classes.

Clinical Trials Miss the Signal

Why did it take decades to recognize this pattern? The answer lies in the demographics of major ARB trials. The LIFE study, which established losartan's benefit in hypertensive patients with left ventricular hypertrophy, enrolled only about 6% Black participants. The VALUE trial, comparing valsartan with amlodipine, had roughly 8% Black enrollment. These numbers are too small for subgroup analyses to detect a differential response.

Even when subgroup analyses are performed, they are often underpowered. A post-hoc analysis of the LIFE trial suggested that losartan's benefit over atenolol was less pronounced in Black participants, but the confidence intervals were wide and the finding was not emphasized in the primary publication. The result was a hidden effectiveness gap: in real-world practice, Black patients on ARBs had higher rates of uncontrolled hypertension than white patients on the same drugs, but the reason was attributed to "poor adherence" or "salt sensitivity" rather than pharmacogenomics.

The underrepresentation of Black participants in clinical trials is not unique to ARB studies — it is a systemic issue across cardiovascular research. But the consequence here is particularly problematic because the very drug class being studied has a predictable, genetically mediated failure mode in the population least represented in the trials.

Some have argued that race-based prescribing guidelines — such as the long-standing recommendation to use thiazide diuretics or calcium channel blockers as first-line therapy in Black patients — were a crude but effective workaround. The CYP3A5 story provides a mechanistic explanation for why those guidelines emerged from clinical experience long before the genetics were understood.

Alternative Pathways in Hypertensive Black Patients

Given the CYP3A5 issue, what should prescribers consider first? The pathophysiology of hypertension in many Black patients is characterized by low renin activity, sodium retention, and expanded plasma volume. This profile makes renin-angiotensin system blockers — including ARBs and ACE inhibitors — less effective as monotherapy compared with drugs that target volume or vascular resistance.

Calcium channel blockers such as amlodipine are highly effective in Black patients, with response rates around 60–70% as monotherapy in some studies. Thiazide-type diuretics, particularly chlorthalidone and indapamide, also work well, likely because they counteract the sodium-retaining tendency. The ALLHAT trial, which included a large proportion of Black participants, found that amlodipine and chlorthalidone were superior to lisinopril in preventing cardiovascular events in Black patients, consistent with the genetic hypothesis.

ACE inhibitors are also affected by genetic polymorphisms — specifically in the ACE gene itself — but the effect is less clear-cut than with CYP3A5 and ARBs. Beta-blockers have not been studied extensively in this context, but they are generally less preferred as first-line therapy in uncomplicated hypertension due to a less favorable metabolic profile.

Combination therapy is often needed. A common effective regimen is amlodipine plus chlorthalidone, or amlodipine plus an ARB if the ARB dose is optimized. The key is to avoid the assumption that an ARB alone will suffice, especially in a CYP3A5 expresser.

Practical Steps for Prescribers

For a Black patient with newly diagnosed hypertension, consider starting with amlodipine 5 mg daily or chlorthalidone 12.5 mg daily. If an ARB is preferred — for example, because of concomitant heart failure or proteinuric kidney disease — start losartan at 50 mg daily and plan to increase to 100 mg at the two-week follow-up if blood pressure is not at goal. Some experts recommend starting at 100 mg directly in known CYP3A5 expressers, but genotyping is not yet widely available.

Monitor blood pressure at two weeks, not the conventional four weeks, because the reduced half-life means the full effect of the initial dose will be apparent earlier. If the response is inadequate, titrate to the maximum approved dose before switching. For losartan, the maximum is 150 mg daily in some guidelines, though 100 mg is more common.

If the patient is already on an ARB with poor control, consider switching to amlodipine or chlorthalidone rather than adding a second agent. The exception is when there is a compelling indication for ARB therapy, such as heart failure with reduced ejection fraction or diabetic nephropathy. In those cases, ensure the ARB dose is maximized and consider adding a low-dose thiazide.

Be aware that adherence may be lower with higher pill burdens. A single-pill combination of amlodipine and an ARB can simplify the regimen, but the ARB component may still be suboptimal if the patient is a CYP3A5 expresser. In that scenario, a combination of amlodipine and chlorthalidone — available as separate pills — may be more reliable.

Trade-offs and Counter-arguments

Some clinicians question whether the CYP3A5 effect is large enough to change practice. They point out that many Black patients achieve adequate blood pressure control on standard ARB doses, and that the variability in response is influenced by many factors beyond genetics — including diet, body weight, and concurrent medications. For example, a patient with high dietary sodium intake may have a blunted response to ARBs regardless of CYP3A5 genotype, and sodium restriction can improve efficacy. Additionally, some ARBs like candesartan and telmisartan have longer half-lives and may be less affected by CYP3A5 metabolism, though direct comparisons are lacking.

Another counter-argument is that the evidence linking CYP3A5 genotype to clinical outcomes is still limited. Most studies have been small pharmacokinetic investigations, not large randomized trials with hard endpoints like stroke or myocardial infarction. A 2020 meta-analysis of five studies found that CYP3A5 expressers had a 3–5 mmHg smaller reduction in systolic blood pressure on losartan compared with non-expressers, but the confidence intervals were wide and the analysis included fewer than 500 patients total. Critics argue that until larger trials are done, it is premature to recommend genotype-guided dosing.

There is also the concern that focusing on CYP3A5 could lead to underuse of ARBs in Black patients who would benefit from them. For instance, a Black patient with heart failure and reduced ejection fraction may derive mortality benefit from an ARB even if blood pressure reduction is modest. In such cases, the ARB should not be withheld; rather, the dose should be optimized and additional agents added as needed. The key is to avoid the assumption that an ARB alone will suffice, not to avoid ARBs entirely.

Finally, the cost and logistics of genotyping remain barriers. A point-of-care test for CYP3A5 may cost $50–100, and many insurance plans do not cover it. In resource-limited settings, the practical approach may still be to start with a thiazide or calcium channel blocker, which are inexpensive and effective regardless of genotype. This aligns with the current JNC 8 and ACC/AHA guidelines, which recommend thiazides or calcium channel blockers as first-line therapy in Black patients, though they do not specifically mention CYP3A5.

Future Directions: Pharmacogenomics in Primary Care

Point-of-care genotyping for CYP3A5 is becoming feasible. Several companies offer rapid tests that can detect the *1/*3 genotype from a buccal swab in about an hour, with costs in the range of US$ 50–100. A pilot clinic at Duke University has been using CYP3A5 genotyping to guide antihypertensive prescribing in Black patients, with early results suggesting improved blood-pressure control and fewer medication switches.

Integration into electronic health record (EHR) alert systems is the next step. If a prescriber orders losartan for a Black patient and the genotype is known, an alert could recommend a higher starting dose or suggest an alternative class. Several large health systems are piloting such alerts, though widespread adoption remains years away.

There are barriers. Genotyping adds cost and time to a primary care visit that is already stretched. Many patients are wary of genetic testing due to privacy concerns or historical misuse of genetic data in minority populations. And the evidence base, while growing, is still not robust enough to mandate testing — most guidelines still do not recommend routine CYP3A5 genotyping.

Nevertheless, the trajectory is toward more individualized prescribing. As the cost of sequencing drops and the evidence accumulates, pharmacogenomics may become a routine part of hypertension management, much as CYP2C19 genotyping is now used for clopidogrel prescribing in some centers. The goal is not to eliminate race from clinical decision-making entirely, but to replace crude demographic proxies with precise biological markers.

The Bottom Line for Daily Practice

Angiotensin receptor blockers are not universally effective. In Black patients, the CYP3A5*1 allele is a common and predictable cause of reduced efficacy at standard doses. Prescribers should be aware of this and adjust their initial choices accordingly — either by selecting a drug class less affected by the polymorphism, such as calcium channel blockers or thiazides, or by starting ARBs at higher doses and titrating aggressively.

Genetic testing for CYP3A5 is not yet standard, but it is on the horizon. In the meantime, clinical judgment guided by an understanding of the underlying biology can close some of the effectiveness gap. The era of one-size-fits-all antihypertensive therapy is ending, and the CYP3A5 story is a clear example of why.

For related reading on how health systems respond to treatment disparities, see this report on workforce changes and this analysis of drug access barriers.

Disclaimer: This article is for informational purposes only and does not constitute personalised medical advice. Always consult a qualified healthcare professional before making changes to medication.